Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE (ESPE 2018)

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Symposia

Management of Late Effects of Cancer Therapy

hrp0089s4.2 | Management of Late Effects of Cancer Therapy | ESPE2018

Hypogonadism in Girls after Cancer Therapy: Causes, Diagnosis, and Treatment

Sklar Charles

Hypogonadism, both primary and secondary, are well documented following cancer therapy. Primary ovarian insufficiency (POI) has most often been associated with exposure to alkylating agents (dose response) and radiation (RT) that includes the ovary (dose response). Early onset POI occurs commonly in girls exposed to ovarian RT at doses >10 Gy and following high-dose alkylating agents as is given for stem cell transplant. Late onset POI (ie, premature menopause) may be seen...

hrp0089s4.3 | Management of Late Effects of Cancer Therapy | ESPE2018

Diagnosis and Treatment of Hypogonadism in Male Survivors of Childhood Cancer

Chemaitilly Wassim

Gonadal dysfunction is among the most commonly reported endocrine late effects in childhood cancer survivors (CCS). The main risk factors include the exposure of the hypothalamic-pituitary-gonadal axis to radiotherapy and treatment with gonadotoxic chemotherapy drugs such as alkylating agents. Individuals may experience gonadal dysfunction because of central (or hypogonadotropic) hypogonadism or as a result of primary gonadal injury. The testes have two distinct functional ent...